A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: The Treat-to-Target (3T) Study

Clinical Therapeutics

Volumn 25, Issue 1, 2003, Pages 119-138

  Olsson, Anders G ^a   Eriksson, Mats ^b   Johnson, Owe ^c   Kjellström, Thomas ^d   Lanke, Jan ^e   Larsen, Mogens Lytken ^f   Pedersen, Terje ^g   Tikkanen, Matti J ^h   Wiklund, Olov ⁱ  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^d HELSINGBORG HOSPITAL   (Sweden)

^e LUND UNIVERSITY   (Sweden)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g AKER UNIVERSITY HOSPITAL   (Norway)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Atorvastatin; Cardiovascular disease; Low density lipoprotein cholesterol; Simvastatin; Triglycerides

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANGINA PECTORIS; ARTICLE; BRAIN INFARCTION; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FASCIITIS; FEMALE; HEART FAILURE; HEART INFARCTION; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; MYOSITIS; RANDOMIZED CONTROLLED TRIAL; TIME SERIES ANALYSIS; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0037277008     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)90015-4     Document Type: Article

References (32)

1. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;89:1329-1445.
2. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
3. Workshop: Treatment of hyperlipidaemia. Läkemedelsverket/The Medical Products Agency. 1995;3:95.
4. Workshop: Treatment of hyperlipidaemia. Läkemedelsverket/The Medical Products Agency. 1999;7:15-73.
5. Prevention of coronary heart disease: Scientific background and new clinical guidelines. Recommendations of the European Atherosclerosis Society prepared by the International Task Force for Prevention of Coronary Heart Disease. Nutr Metabol Cardiovasc Dis. 1992;2:113-156.
6. Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis. 1998;140:199-270.
7. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: An eight-year follow-up in the Copenhagen Male Study. Circulation. 1998;97:1029-1036.
8. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81(4A):7B-12B.
9. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
10. Altman DG. Practical Statistics for Medical Research. London: Chapman & Hall; 1991.
11. Dart A, Jerums G, Nicholson G, et al. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol. 1997;80:39-44.
12. Davidson M, McKenney J, Stein E, et al, for the Atorvastatin Study Group. I. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol. 1997;79:1475-1481.
13. Bertolini S, Bon GB, Campbell LM, et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis. 1997;130:191-197.
14. Insull W, Kafonek S, Goldner D, Zieve F, for the ASSET Investigators. Comparison of efficacy and safety of atorvastatin (10 mg) with simvastatin (10 mg) at six weeks. Am J Cardiol. 2001;87:554-559.
15. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES Study). Am J Cardiol. 1998;81:582-587
16. März W, Wollschläger H, Klein G, et al. Safety of low-density lipoprotein cholesterol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial). Am J Cardiol. 1999;84:7-13.
17. Kastelein J, Isaacsohn JL, Ose L, et al. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol. 2000;86:221-223.
18. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;304:1383-1389.
19. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
20. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
21. Koren MJ, Smith DG, Hunninghake DB, et al. The cost of reaching National Cholesterol Education Panel (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin. Pharmacoeconomics. 1998;14:59-70.
22. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351-364.
23. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223:405-418.
24. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
25. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
26. Pitt B, Waters D, Brown WV, et al, for the Atorvastatin Versus Revasculanzation Treatment Investigators. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med. 1999;341:70-76.
27. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997;336:153-162.
28. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomised, double-blind trial. Lancet. 2001;357:577-581.
29. Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 1998;97:1453-1460.
30. LaRosa for the TNT Steering Committee. Effect of lowering LDL-C beyond currently recommended minimum targets - the Treating to New Targets (TNT) study. Poster presented at: XIIIth International Symposium on Drugs Affecting Lipid Metabolism; Florence, Italy; May 30-June 3, 1998.
31. Pedersen TR, Faergeman O, Holme I, et al. Effect of greater LDL-C reductions on prognosis - the Incremental Decrease in Endpoints through Aggressive Lipid lowering (IDEAL) trial. Atherosclerosis. 1999;144:38.
32. Black DM, Bakker-Arkema RG, Nawrocki JW. An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor. Arch Intern Med. 1998;158:577-584.